Prolor Biotech (PBTH +8.2%) hires Jefferies Group to evaluate strategic alternatives. An unnamed source says the company has drawn interest from big pharma over the past 12 months, but notes PBTH has not decided to sell itself. SA contributor Daniel Lauchheimer's article suggesting the stock has "unlimited upside" looks prescient. (See also: PBTH gets orphan drug designation)
Prolor Biotech (PBTH +8.2%) hires Jefferies Group to evaluate strategic alternatives. An unnamed...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs